Core Insights - Corbus Pharmaceuticals is presenting at the 44th Annual JPMorgan Healthcare Conference, focusing on key assets and upcoming milestones [1][2] Group 1: Upcoming Milestones - The company plans to highlight important milestones for its ADC (Antibody-Drug Conjugate) this year [2] - A significant focus will be on the maturing data for CRB-701, particularly regarding its second-line monotherapy in head and neck cancer [3] Group 2: Data Presentation - Updated data on CRB-701 was presented at ESMO, indicating an increase in patient numbers and longer duration of response [3] - The company aims to present further maturing data at a large oncology conference later this year, emphasizing the duration of response for patients [4]

Summary of Corbus Pharmaceuticals FY Conference Call Company Overview - **Company**: Corbus Pharmaceuticals (NasdaqCM:CRBP) - **Date of Conference**: January 15, 2026 - **Key Speaker**: CEO Yuval Cohen Key Points on Drug Development and Pipeline CRB-701 (Oncology) - **Indications**: Focus on second-line monotherapy for head and neck cancer and cervical cancer - **Data Presentation**: Updated data presented at ESMO, with emphasis on the duration of response for patients in second-line head and neck cancer [3] - **FDA Discussions**: Ongoing discussions with the FDA regarding the registrational pathway for CRB-701 in both head and neck and cervical cancers, with expectations of clarity on the regulatory process [4][5] - **Durability of Response**: Key question remains on how durable the response is for patients treated with CRB-701 in both indications [3][4] - **First-Line Treatment**: Emerging data from a study combining CRB-701 with Keytruda in first-line head and neck cancer, with expectations for data maturation later in the year [5][6] CRB-913 (Obesity) - **Mechanism**: A once-a-day oral small molecule CB1 inverse agonist, with a focus on obesity treatment [8] - **Comparison with Monlunabant**: CRB-913 is more restricted in the brain compared to Monlunabant, leading to potentially fewer adverse effects [10][11] - **Safety Profile**: Initial phase 1A data shows a mild profile of gastrointestinal adverse events, significantly better than Monlunabant, which had higher GI toxicity [15][19] - **Neuropsychiatric Events**: No clinical events of neuropsychiatric adverse events reported in CRB-913 trials, contrasting with Monlunabant's high incidence [18][19] - **Weight Loss Results**: Significant weight loss observed in participants, with an average of nearly 3% weight loss after one week of dosing [20][21] - **Efficacy Comparison**: CRB-913 shows potential to be more potent than Rimonabant and Monlunabant, with a promising safety profile [25][27] Financial Position - **Cash Reserves**: Corbus Pharmaceuticals reported having $172 million in cash, providing a runway for both oncology and obesity programs into 2028 [44] Additional Insights - **Regulatory Environment**: The current FDA environment is perceived as less welcoming to single-arm accelerated approval studies compared to previous years [4] - **Market Positioning**: The company aims to position CRB-701 in a competitive landscape dominated by EGFR combinations in first-line head and neck cancer [6] - **Future Milestones**: Anticipated data releases and regulatory updates for both CRB-701 and CRB-913 throughout 2026 [33] Conclusion Corbus Pharmaceuticals is actively advancing its oncology and obesity drug pipelines, with significant upcoming milestones and a strong financial position to support its initiatives. The focus on safety and efficacy in both CRB-701 and CRB-913 highlights the company's commitment to addressing unmet medical needs in these therapeutic areas.

Group 1 - Corbus Pharmaceuticals Holdings Inc. is a clinical-stage company focused on oncology and obesity, with a commitment to innovative scientific approaches to serious illnesses [2] - The company will present a corporate overview at the 2026 Annual J.P. Morgan Healthcare Conference scheduled for January 12-15, 2026, in San Francisco, CA [1] - Corbus' pipeline includes CRB-701, a next-generation antibody drug conjugate targeting Nectin-4 on cancer cells; CRB-601, an anti-integrin monoclonal antibody blocking TGFβ activation; and CRB-913, a CB1 inverse agonist for obesity treatment [2]

Core Insights - Several small-cap biotech and healthcare companies experienced notable gains in after-hours trading, driven by recent corporate updates and clinical milestones Company Updates - Inspira Technologies Oxy B.H.N. Ltd. (IINN) rose 5.88% to $1.08 following a recent definitive agreement for a registered direct offering of its ordinary shares and a Standby Equity Purchase Agreement with YA II PN, Ltd. [2] - Galectin Therapeutics Inc. (GALT) increased by 1.79% to close at $6.27, despite no new corporate developments reported [3] - MediciNova, Inc. (MNOV) advanced 4.83% to $1.52 after successfully completing patient enrollment in its Phase 2 OXTOX study, evaluating MN-166 for chemotherapy-induced peripheral neuropathy in metastatic colorectal cancer patients [4] - Marker Therapeutics, Inc. (MRKR) gained 5.56% to $1.33 without any new company-specific announcements [5] - Sharps Technology, Inc. (STSS) climbed nearly 4% to $2.09, also without fresh updates [6] - DiaMedica Therapeutics Inc. (DMAC) rose 2.89% to $8.55 after a productive pre-IND meeting with the FDA regarding its planned study of DM199 in preeclampsia [6] - Corbus Pharmaceuticals Holdings, Inc. (CRBP) edged higher by 1.36% to $8.21, following the completion of its Phase 1a study of CRB-913 and initiation of the Phase 1b CANYON-1 trial [7] - ProMIS Neurosciences, Inc. (PMN) added 0.83% to $8.49, recovering slightly after a decline earlier in the day, with the completion of enrollment of 144 patients in its PRECISE-AD Phase 1b clinical trial for Alzheimer's disease [8]

Core Viewpoint - Corbus Pharmaceuticals held an investor webinar to discuss recent results related to their single-ascending and multiple-ascending dose studies [2]. Group 1: Company Overview - Yuval Cohen, the CEO and Director of Corbus Pharmaceuticals, led the webinar and expressed gratitude for the participants' attendance [2]. - The company is focusing on forward-looking statements regarding their research and development efforts [2]. Group 2: Expert Involvement - Dr. Sarah Barenbaum, an Assistant Professor of Clinical Medicine at Weill Cornell Medical College, joined the discussion to provide insights on the data announced [3]. - Dr. Barenbaum specializes in obesity and weight-related medical complications, indicating the company's focus on relevant medical fields [3].

Corbus Pharmaceuticals Holdings (NasdaqCM:CRBP) Update Summary Company Overview - **Company**: Corbus Pharmaceuticals Holdings - **Event**: Investor Webinar held on December 11, 2025 Key Points Industry and Product Focus - The discussion centers around the development of **CRB-913**, a novel **CB1 inverse agonist** aimed at treating obesity and weight-related medical complications [1][2][5] - Comparison is made with **Monlunabant**, another CB1 inverse agonist, highlighting differences in brain exclusion and safety profiles [5][6][11] Clinical Study Insights - **Study Design**: The **Single Ascending Dose (SAD)** and **Multiple Ascending Dose (MAD)** studies involved healthy volunteers and participants with obesity, focusing on safety and pharmacokinetics (PK) [6][7][8] - **Dosing**: CRB-913 was administered at doses up to **600 mg**, significantly higher than effective doses of Monlunabant [7] - **Safety Profile**: CRB-913 exhibited a favorable safety profile with minimal gastrointestinal (GI) adverse events, contrasting sharply with Monlunabant, which had a high incidence of GI issues [9][10][11] Efficacy and Weight Loss Results - Participants in the obesity cohort (average BMI of **36**) experienced weight loss of **2.9%** over **14 days**, with no weight loss in the placebo group [13][52] - Weight loss was not associated with GI adverse events, indicating a unique mechanism of action for CRB-913 [22][39] - The drug demonstrated a long half-life, contributing to sustained weight loss effects beyond the dosing period [45][46] Neuropsychiatric Safety - CRB-913 showed no significant neuropsychiatric adverse events, with validated questionnaires indicating no cases of suicidality or depression among participants [11][12][25] - Mild anxiety was reported in a few cases, but these did not trigger any significant concerns [26][27] Future Directions - Corbus Pharmaceuticals plans to initiate **CANYON-1**, a Phase 1b study focusing on safety and tolerability, with a titration approach to dosing [19][20] - The company aims to learn from Monlunabant's experiences to improve patient outcomes and safety [19][20] Market Context and Need - There is a recognized need for diverse treatment options in obesity management, as many patients do not respond adequately to existing therapies, particularly GLP-1 agonists [33][34][35] - The potential for combination therapies targeting different pathways in obesity treatment is emphasized [34][35] Conclusion - The data presented indicates that CRB-913 has a promising profile as a treatment for obesity, with early indications of efficacy and a favorable safety profile compared to existing therapies [22][39][56] - Further studies are necessary to confirm these findings and establish the drug's role in clinical practice [56][58]

Core Insights - Corbus Pharmaceuticals has completed the Phase 1a study of CRB-913 and initiated a Phase 1b study, with results expected in summer 2026 [1][8] Study Overview - The Phase 1a study included a double-blinded placebo-controlled design, assessing safety, tolerability, and pharmacokinetics of CRB-913 with a maximum dose of 600 mg/day [2] - The study involved 64 participants in the single ascending dose (SAD) portion and 48 participants in the multiple ascending dose (MAD) portion [2] Safety and Tolerability - No serious treatment-emergent adverse events were reported, and CRB-913 showed no gastrointestinal intolerability [3] - Neuropsychiatric assessments indicated stability with no reported cases of suicidality, depression, or insomnia [4][5] Efficacy Results - In the obese MAD cohort, participants treated with CRB-913 experienced a placebo-adjusted mean weight loss of 2.9% by Day 14, with individual weight loss ranging from 1.3% to 4.3% [6][8] - Participants reported a reduction in food-related thoughts and cravings, indicating potential efficacy in weight management [6] Future Developments - The Phase 1b CANYON-1 study will involve 240 obese, non-diabetic participants and will assess three dosing cohorts of CRB-913 [11] - The study design includes a dose titration regimen starting at 20 mg/day [11] About CRB-913 - CRB-913 is a peripherally restricted CB1 inverse agonist designed to minimize brain penetration, potentially reducing neuropsychiatric risks associated with earlier drugs in this class [12]

Core Insights - After-hours trading in the U.S. saw significant gains in small-cap and micro-cap biotech stocks, driven by a mix of catalyst-driven moves and sentiment-based rebounds following the Fed's rate cut Group 1: Notable After-Hours Gainers - Agape ATP Corp. (ATPC) surged 29.41% after hours to $0.088, despite no specific news, reflecting a broader risk-on sentiment in micro-cap stocks [1] - Corbus Pharmaceuticals Holdings, Inc. (CRBP) rose 12.76% after hours to $11.57, driven by anticipation of a key clinical update on its Phase 1a study of CRB-913 [2] - Anebulo Pharmaceuticals, Inc. (ANEB) increased 8.37% after hours to $2.33, aligning with the overall positive sentiment in small-cap biotech [3] - Cue Biopharma, Inc. (CUE) gained 13.12% after hours to $0.54, with no new developments, indicating a macro-driven recovery in biotech [4] - Curis, Inc. (CRIS) saw a 7.68% increase after hours to $1.3999, following positive clinical data presented at the ASH Annual Meeting [5] - Skye Bioscience, Inc. (SKYE) rose 7.02% after hours to $1.22, benefiting from the overall biotech market lift [6] - Cerus Corporation (CERS) increased 3.17% after hours to $1.95, continuing its upward trend after announcing a purchasing agreement with Blood Centers of America [7]

Core Insights - Corbus Pharmaceuticals Holdings Inc. plans to release results of its Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) study of CRB-913 on December 11, 2025, before market open [1] - A conference call and live webcast will be held on the same day at 8:00 am ET to discuss the Phase 1a data [1] About CRB-913 - CRB-913 is an oral small molecule inverse agonist of the G-protein Coupled Receptor (GPCR) cannabinoid type-1 (CB1), designed for weight loss with reduced brain penetration [3] - Preclinical models indicate that CRB-913 is 15-fold less brain-penetrant than monlunabant and has a 50 times lower brain:plasma ratio than rimonabant [3] About Corbus - Corbus Pharmaceuticals is focused on oncology and obesity, aiming to address serious illnesses through innovative scientific approaches [4] - The company's pipeline includes CRB-701, an antibody drug conjugate targeting Nectin-4 on cancer cells, and CRB-601, an anti-integrin monoclonal antibody blocking TGFβ activation on cancer cells [4]

Summary of Corbus Pharmaceuticals Holdings FY Conference Call Company Overview - Corbus Pharmaceuticals Holdings is a drug development company based in Norwood, Massachusetts, with a focus on oncology and obesity [4][5] - The company has a small team of approximately 40 employees and emphasizes its preference for remaining small [4] Key Pipeline Developments ADC Program for Nectin-4 - The company is focusing on its ADC program for Nectin-4, with key milestones expected in the next 18 months [7] - Upcoming regulatory updates and data releases are planned for: - Q1: Regulatory update on pivotal study for Nectin-4 ADC monotherapy in second-line head and neck cancer [5] - Mid-year: Data on monotherapy for head and neck cancer, with a focus on durability [5] - Second half of the year: Data on monotherapy for cervical cancer and combination therapy with Keytruda in front-line head and neck cancer [5][6] CB1 Program for Obesity - The company is preparing to release SAD/MAD data imminently, with a significant study on obese non-diabetics planned for mid-year [6][19] - The phase 1 study design includes a classic SAD/MAD approach, with dosing up to hundreds of milligrams per day to assess safety and pharmacokinetics [19][20] Market Context and Competitive Landscape - The second-line treatment landscape for head and neck cancer is described as grim, with current therapies offering limited efficacy [7][8] - The company aims to differentiate its therapies based on safety profiles, particularly in terms of lower neuropathy and ocular toxicity compared to competitors like Padcev [16][17] Financial Position - Corbus Pharmaceuticals has extended its cash runway into 2028, providing a stable financial foundation for upcoming studies and developments [7] Strategic Focus - The company prioritizes investment in second-line monotherapy for head and neck cancer, followed by cervical cancer, with a wildcard focus on front-line combination therapy [30][32] - The potential for combination therapies with GLP-1 agonists is also being explored, with preclinical data showing promising results [28][29] Additional Insights - The company is cautious about expanding its focus beyond its current pipeline due to resource limitations, although it remains open to exploring other tumor types that express Nectin-4 [10][11] - The safety profile of CRB-701 is highlighted as a potential commercial advantage, particularly its low levels of peripheral neuropathy, which is a significant concern for patients [16][17] Conclusion - Corbus Pharmaceuticals is positioned to make significant advancements in its ADC and CB1 programs over the next year, with a clear focus on regulatory milestones and data releases that could shape its future in the oncology and obesity markets [5][6][30]